Drugs / FP-1039
FP-1039
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01868022 | Oct 2013 → Oct 2017 | neoplasm | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01604863 | Jun 2012 → Jun 2014 | cancer | GlaxoSmithKline | Suspended | No outcome recorded |
| Phase 1 | NCT00687505 | Jul 2008 → May 2011 | — | Five Prime Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01244438 | Jan 2011 → Jun 2012 | — | Five Prime Therapeutics, Inc. | Withdrawn | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FP-1039 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00687505 ↗ |
| Known as | Fgf receptor antagonist hgs1036 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297755 ↗ |
| Known as | GSK3052230 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01868022 ↗ |
| Known as | HGS1036 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01604863 ↗ |
| Route | Intravenous | “Intravenous weekly administration” NCT00687505 ↗ |